“The study was phase 1 and designed to assess safety. From evaluating a small number of subjects, THR-687 showed a signal of clinical efficacy based on best corrected visual acuity," noted Arshad Khanani, M.D., M.A., an investigator in the study.
Dr. Khanani presented the topline results at the February 2020 Angiogenesis, Exudation and Degeneration meeting in Miami, Florida. “I was very pleased to present the data of the phase 1 clinical trial of THR-687. They were well received by my colleagues,” he reported.
Why were you pleased with the data?
“The primary endpoint of the study was safety, and THR-687 was found to be safe without any dose-limiting toxicities. The patients received prior treatment with either anti-VEGF or steroid injections and we still saw visual acuity improvements. These were relatively difficult patients to treat. The high-dose group showed clinically meaningful gains in vision and improvements in OCT, which is very encouraging.”
What is the future of THR-687?
“Preclinical studies show that integrins work on several pathways linked to diabetic eye disease. As THR-687 is a pan-RGD integrin antagonist, it can block these pathways and improve sight. The result of the phase 1 clinical trial argues in favor of a phase 2 study in naive DME patients to establish the efficacy and safety of THR-687. These initial data show that THR-687 can potentially be an effective monotherapy or adjunctive therapy for patients with DME.”
Dr. Arshad Khanani, M.D., M.A. is an ophthalmologist and vitreo-retinal specialist and the managing partner and director of clinical research at Sierra Eye Associates, Reno, Nevada, USA. He is a consultant to the company and an investigator for both THR-149 and THR-687 clinical trials.May 5th, 2020